NCT03798314View on ClinicalTrials.gov

Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 30, 2019

Primary Completion Date

December 30, 2020

Study Completion Date

September 15, 2021

Conditions
Recurrent Nervous System LymphomaRecurrent Primary Vitreoretinal DLBCLRefractory Nervous System LymphomaRefractory Primary Vitreoretinal DLBCL
Interventions
BIOLOGICAL

Nivolumab

Given IV

DRUG

Pomalidomide

Given PO

Trial Locations (2)

55905

Mayo Clinic, Rochester

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT03798314 - Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma | Biotech Hunter | Biotech Hunter